A commentary on ‘The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. A cross sectional study’ – a correspondence
Xue-Lei Li, Zhi-Peng Liu, Hai-Su Dai, Xian-Yu Yin, Zhi-Yu Chen · 2023
Read A commentary on ‘The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. A cross sectional study’ – a correspondence by Xue-Lei Li, Zhi-Peng Liu, Hai-Su Dai, Xian-Yu Yin, Zhi-Yu Chen (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10720794.txt.
Description
Xue-Lei Li and co-authors write to question a study that favored chemotherapy before surgery for removable pancreatic cancer, in a 2023 correspondence. The study compared patients who received chemotherapy first against those operated on immediately, and reported better survival for the chemotherapy-first group. The letter writers accept the finding's importance but raise a confound the authors overlooked.
Nearly every chemotherapy-first patient went on to receive post-surgery drug therapy, while only about half of the surgery-first group did. Since that follow-up therapy itself extends survival, the comparison cannot show whether the benefit came from the early chemotherapy or from more total therapy. They suggest re-analysis with both groups' follow-up treatment held consistent. A second point concerns the rates of complete tumor removal between the groups. The letter is offered as a constructive correction to a clinically important comparison.
Catalog record
| CREATOR | Xue-Lei Li, Zhi-Peng Liu, Hai-Su Dai, Xian-Yu Yin, Zhi-Yu Chen |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 4 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |